Literature DB >> 14533499

[Thrombosis prevention in orthopaedic surgery: clinical practice in the Netherlands in 2002].

D Schonenberg1, M van Meeteren, R G Nelissen, I E van der Horst-Bruinsma, R G Pöll, M T Nurmohamed.   

Abstract

OBJECTIVE: Establish the use of thromboprophylaxis in orthopaedic surgery both during and after the hospital admission.
DESIGN: Cross-sectional study.
METHOD: In April 2002, a letter was sent to all orthopaedic surgeons in the Netherlands announcing that at every hospital with a Department of Orthopaedic Surgery, an orthopaedic surgeon would be approached for a telephone survey. They were phoned in the months April-June 2002. This study included hospitals where major orthopaedic surgery (e.g. the insertion of hip or knee prostheses and hip fracture surgery) took place (n = 124) as well as clinics that only performed day treatments (n = 5).
RESULTS: For major orthopaedic operations, 91% of the hospitals used low molecular weight heparin (LMWH) during the admission period: 36% as monotherapy and 55% in combination with coumarin derivates. In 85% of cases the use of LMWH was started preoperatively. Coumarin derivates were used as a monotherapy in 9% of the hospitals. In 37% of the hospitals the use of NSAIDs was continued, particularly in patients with rheumatoid arthritis. In 94% of the hospitals, the use of acetylsalicylic acid was always stopped. In 97% of the hospitals prophylaxis was given after discharge in the form of LMWH (37% of the cases) or coumarin derivates (63% of the cases). The use of thromboprophylaxis with respect to arthroscopies and plaster immobilisation was variable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533499

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  Dutch orthopedic thromboprophylaxis: a 5-year follow-up survey.

Authors:  Harmen B Ettema; Marieke C Mulder; Michael T Nurmohamed; Harry R Büller; Cees C P M Verheyen
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.